Brokerages expect bluebird bio (NASDAQ:BLUE) to announce earnings of ($2.27) per share for the current fiscal quarter, Zacks reports. Six analysts have made estimates for bluebird bio’s earnings. The highest EPS estimate is ($0.84) and the lowest is ($2.55). bluebird bio reported earnings of ($1.73) per share in the same quarter last year, which would suggest a negative year over year growth rate of 31.2%. The firm is expected to announce its next quarterly earnings report on Wednesday, August 1st.
According to Zacks, analysts expect that bluebird bio will report full-year earnings of ($9.33) per share for the current fiscal year, with EPS estimates ranging from ($10.89) to ($4.74). For the next fiscal year, analysts forecast that the company will report earnings of ($9.23) per share, with EPS estimates ranging from ($12.17) to ($3.81). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that follow bluebird bio.
Get bluebird bio alerts:
bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings results on Monday, May 7th. The biotechnology company reported ($2.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.01) by ($0.30). The company had revenue of $15.96 million during the quarter, compared to analyst estimates of $5.85 million. bluebird bio had a negative net margin of 857.55% and a negative return on equity of 27.61%. The company’s revenue was up 133.7% on a year-over-year basis. During the same period in the prior year, the company earned ($1.68) earnings per share.
Several analysts recently issued reports on the stock. Maxim Group reaffirmed a “hold” rating and issued a $200.00 price target on shares of bluebird bio in a report on Thursday, February 22nd. Canaccord Genuity reaffirmed a “buy” rating and issued a $250.00 price target on shares of bluebird bio in a report on Tuesday, March 13th. Leerink Swann cut shares of bluebird bio from an “outperform” rating to a “market perform” rating and upped their price target for the company from $162.00 to $194.00 in a report on Thursday, January 25th. SunTrust Banks upped their price target on shares of bluebird bio to $232.00 and gave the company a “buy” rating in a report on Thursday, April 19th. Finally, BidaskClub raised shares of bluebird bio from a “buy” rating to a “strong-buy” rating in a report on Friday, January 26th. Four investment analysts have rated the stock with a sell rating, nine have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $195.80.
BLUE traded down $5.60 during trading on Friday, hitting $183.70. The company had a trading volume of 665,896 shares, compared to its average volume of 778,666. The stock has a market capitalization of $8.94 billion, a PE ratio of -23.83 and a beta of 2.17. bluebird bio has a 1-year low of $74.45 and a 1-year high of $236.17.
In other bluebird bio news, insider David Davidson sold 13,000 shares of the business’s stock in a transaction on Wednesday, May 2nd. The shares were sold at an average price of $177.52, for a total transaction of $2,307,760.00. Following the completion of the sale, the insider now owns 37,905 shares in the company, valued at $6,728,895.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Mark Vachon sold 6,000 shares of the business’s stock in a transaction on Thursday, March 15th. The shares were sold at an average price of $214.38, for a total transaction of $1,286,280.00. Following the sale, the director now owns 7,000 shares of the company’s stock, valued at approximately $1,500,660. The disclosure for this sale can be found here. In the last quarter, insiders have sold 46,250 shares of company stock valued at $8,269,990. 3.90% of the stock is owned by insiders.
Several institutional investors have recently added to or reduced their stakes in the company. Hanseatic Management Services Inc. grew its position in shares of bluebird bio by 14.6% during the fourth quarter. Hanseatic Management Services Inc. now owns 2,334 shares of the biotechnology company’s stock worth $416,000 after acquiring an additional 298 shares during the last quarter. Commonwealth Equity Services LLC grew its position in shares of bluebird bio by 24.7% during the first quarter. Commonwealth Equity Services LLC now owns 1,936 shares of the biotechnology company’s stock worth $330,000 after acquiring an additional 383 shares during the last quarter. Winfield Associates Inc. grew its position in shares of bluebird bio by 12.4% during the first quarter. Winfield Associates Inc. now owns 3,620 shares of the biotechnology company’s stock worth $618,000 after acquiring an additional 400 shares during the last quarter. Macquarie Group Ltd. grew its position in shares of bluebird bio by 2.3% during the fourth quarter. Macquarie Group Ltd. now owns 19,102 shares of the biotechnology company’s stock worth $3,402,000 after acquiring an additional 438 shares during the last quarter. Finally, Kazazian Asset Management LLC grew its position in shares of bluebird bio by 11.6% during the fourth quarter. Kazazian Asset Management LLC now owns 4,555 shares of the biotechnology company’s stock worth $811,000 after acquiring an additional 472 shares during the last quarter.
bluebird bio Company Profile
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent -thalassemia and severe sickle cell disease.
Get a free copy of the Zacks research report on bluebird bio (BLUE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com